


8465834



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 6, 2024

**THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON**

October 20, 2022

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office



Breaun Johnson
Certifying Officer

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7600063

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DENIS DRYGIN	09/30/2022
GARTH A. KINBERGER	10/08/2022
EDMUND CHUN YU LEE	09/30/2022
RECEIVING PARTY DATA	
Name:	REGULUS THERAPEUTICS INC.
Street Address:	10628 SCIENCE CENTER DRIVE
Internal Address:	SUITE 100
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	63253933
CORRESPONDENCE DATA	
Fax Number:	(617)812-1277
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174304740
Email:	angela.zontelli@mcneillbaur.com
Correspondent Name:	MCNEILL BAUR PLLC
Address Line 1:	125 CAMBRIDGE PARK DRIVE
Address Line 2:	SUITE 301
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02140
ATTORNEY DOCKET NUMBER:	01138-0043-60US
NAME OF SUBMITTER:	ANGELA M. ZONTELLI
SIGNATURE:	/Angela M. Zontelli/
DATE SIGNED:	10/20/2022
Total Attachments: 2	
source=01138-0043-60US_Assignment_Executed#page1.tif	
source=01138-0043-60US_Assignment_Executed#page2.tif	

507553174

PATENT
REEL: 061477 FRAME: 0475

SOLE/JOINT INVENTION
(Worldwide Rights)
Attorney Docket No. 01138-0043-60US

ASSIGNMENT

WHEREAS we, the below named inventors (hereinafter referred to as Assignors) have made an invention entitled:

METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE

for which was filed United States Provisional Application No. 63/253,933 on October 8, 2021, and

WHEREAS, Regulus Therapeutics Inc., a corporation having a place of business at 10628 Science Center Dr., Suite 100, San Diego, CA 92121 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and to any applications filed in any worldwide jurisdiction claiming the benefit of priority of that provisional patent application as well as any Letters Patent to be issued claiming the benefit of priority of the provisional application;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, including provisional Application No. 63/253,933, filed October 8, 2021, including all rights to claim the benefit of priority in any worldwide patent jurisdiction to Application No. 63/253,933, and including any application claiming the benefit of priority to Application No. 63/253,933 and any Letters Patent granted thereon including any renewals, extensions, or reissues of such Letters Patent. We hereby authorize and request any official of any jurisdiction whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country.


IN TESTIMONY WHEREOF, we have hereunto set our hands.

DocuSigned by: <i>Denis Drygin</i> Denis Drygin	September 30, 2022 DATE
DocuSigned by: <i>Garth A. Kimberger</i> Garth A. Kimberger	October 8, 2022 DATE
DocuSigned by: <i>Ed Lee</i> Edmund Chun Yu Lee	September 30, 2022 DATE

SOLE/JOINT INVENTION
(Worldwide Rights)
Attorney Docket No. 01138-0043-60US

IN TESTIMONY WHEREOF, ASSIGNEE acknowledges this assignment and hereunto signed
ASSIGNEE'S name to this Assignment on the date indicated below.

REGULUS THERAPEUTICS INC.

By:  _____

Date: October 10, 2022

Name: Christopher Aker

Title: SVP & General Counsel